DES Education and Research Amendments of 1992
PL 102-409 (H.R.4178), enacted 10/13/1992

106 STAT. 2092 
PUBLIC LAW 102-409—OCT. 13, 1992 
Public Law 102-409 
102d Congress 
An Act 
To amend the Public Health Service Act to provide for a program to cany out 
Oct. 13, 1992 
research on the drug known as diethylstilbestrol, to educate health professionals 
[H.R. 4178] 
ai^d the public on the drug, and to provide for certain longitudinal studies regard-
ing individuals who have been exposed to the drug. 
Be it enacted by the Senate and House of Representatives 
of 
DES Education 
ffig United States of America in Congress assembled, 
and Research 
A^mendments of 
SECTION 1. SHORT TITLE. 
42 use 201 note. 
This Act may be cited as the "DES Education and Research 
Amendments of 1992". 
SEC. 2. ESTABUSHMENT OF PROGRAM REGARDING DES. 
Part A of title IV of the PubUc Health Service Act (42 U.S.C. 
281 et seq.) is amended by adding at the end the following new 
section: 
"DES 
42 use 283a. 
«SEC. 403A. (a) The Director of NIH shall establish a program 
for the conduct and support of research and training, the dissemina-
tion of health information, and other programs with respect to 
the diagnosis and treatment of conditions associated with exposure 
to the drug diethylstilbestrol (in this section referred to as *DES*). 
"(b) In carrying out subsection (a), the Director of NIH, after 
consultation with nonprofit private entities representing individuals 
who have been exposed to DES, shall conduct or support programs 
to educate health professionals and the public on the drug, including 
the importance of identifying and treating individuals who have 
been exposed to the drug. 
"(c) After consultation with the Office of Research on Women's 
Health, the Director of NIH, acting through the appropriate national 
research institutes, shall in carrying out subsection (a) conduct 
or support one or more longitudinal studies to determine the 
incidence of the following diseases or disorders in the indicated 
populations and the relationship of DES to the diseases or disorders: 
"(1) In the case of women to whom (on or after January 
1, 1938) DES was administered while the women were preg-
nant, the incidence of all diseases and disorders (including 
breast cancer, gynecological cancers, and impairments of the 
immiine system, including autoimmune disease). 
"(2) In the case of women exposed to DES in utero, the 
incidence of clear cell cancer (including recurrences), the long-
term health effects of such cancer, and the effects of treatments 
for such cancer. 
"(3) In the case of men and women exposed to DES in 
utero, the incidence of all diseases and disorders (including 
impairments of the reproductive £Uid autoimmune systems). 
"(4) In the case of children of men or women exposed 
to DES in utero, the incidence of all diseases and disorders. 
PUBLIC LAW 102-409—OCT. 13, 1992 
106 STAT. 2093 
"(d) For purposes of this section, an individual shall be consid-
ered to have been exposed to DES in utero if, during the pregnancy 
that resulted in the birth of such individual, DES was (on or 
after January 1, 1938) administered to the biological mother of 
the individual. 
"(e) In addition to any other authorization of appropriations Appropriation 
available for the purpose of carrying out this section, there are authorization. 
authorized to be appropriated for such purpose such sums as may 
be necessary for each of the fiscal years 1993 through 1996.". 
Approved October 13, 1992. 
LEGISLATIVE HISTORY—H.R. 4178 (S. 2837): 
HOUSE REPORTS: No. 102-817 (Coram, on Energy and Ck)mmerce). 
SENATE REPORTS: No. 102-413 accompanying S. 2837 (Comm. on Labor and Human 
CONGRESSIONAL RECORD, Vol. 138 (1992): 
Aug. 10, considered and passed House. 
Sept. 30, considered and passed Senate.